Page last updated: 2024-12-10

14,15-dihydroxyeicosatrienoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 14,15-Dihydroxyeicosatrienoic acid (14,15-DiHETrE): A Lipid Mediator with Potential in Research

14,15-DiHETrE is a **lipid mediator** derived from the metabolism of arachidonic acid. It's specifically generated by the enzyme **15-lipoxygenase-1 (15-LOX-1)**, which is found in various tissues like the skin, lungs, and platelets.

**Why is it important for research?**

14,15-DiHETrE has garnered attention due to its diverse range of biological activities, making it a crucial subject in various research fields:

* **Inflammation and Immunology:** 14,15-DiHETrE has been shown to **inhibit inflammation**, possibly by interfering with the activation of certain immune cells. This makes it a potential target for developing new anti-inflammatory therapies.
* **Cardiovascular Disease:** 14,15-DiHETrE is linked to **blood vessel relaxation** and may play a role in regulating blood pressure. Research is exploring its potential in preventing and treating cardiovascular diseases.
* **Cancer:** Studies suggest that 14,15-DiHETrE might have **anti-cancer effects**. It can induce apoptosis (programmed cell death) in some cancer cells and inhibit tumor growth in animal models.
* **Neurological Disorders:** Research is investigating the role of 14,15-DiHETrE in **neurological processes**. It may influence nerve cell communication and have implications for conditions like Alzheimer's disease.
* **Wound Healing:** 14,15-DiHETrE might be involved in **promoting wound healing**. It may stimulate collagen production and support tissue repair.

**Challenges in Research:**

Despite its promising potential, research on 14,15-DiHETrE faces certain challenges:

* **Limited understanding:** The precise mechanisms by which 14,15-DiHETrE exerts its effects are not fully understood.
* **Complex interactions:** 14,15-DiHETrE can interact with other lipid mediators, making it difficult to isolate its specific role in various biological processes.
* **Therapeutic development:** Translating the potential benefits of 14,15-DiHETrE into effective therapies remains a complex challenge.

**Overall, 14,15-DiHETrE is a fascinating lipid mediator with potential therapeutic applications. Ongoing research is unraveling its biological roles and exploring its potential in diverse disease settings. Understanding its complex interactions and mechanisms will pave the way for developing novel therapies based on this promising molecule.**

(5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid : A DHET obtained by formal dihydroxylation across the 14,15-double bond of arachidonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283147
CHEMBL ID7514
CHEBI ID63966
SCHEMBL ID2508726
MeSH IDM0278611

Synonyms (22)

Synonym
(+/-)14,15-dihetre
14,15-dihydroxy-5z,8z,11z-eicosatrienoic acid
LMFA03050010
(5z,8z,11z)-14,15-dihydroxyeicosa-5,8,11-trienoic acid
14,15-dhet
(5z,8z,11z)-14,15-dihydroxyicosa-5,8,11-trienoic acid
14,15-dihydroxyeicosatrienoic acid
chebi:63966 ,
CHEMBL7514
14,15-dihetre
(5z,8z,11z)-14,15-dihydroxyicosatrienoic acid
SCHEMBL2508726
(+/-)14,15-dihydroxy-5z,8z,11z-eicosatrienoic acid
(5z,8z,11z)-14,15-dihydroxyicosa-5,8,11-trienoate
14,15-dihydroxyeicosatrienoate
(5z,8z,11z)-14,15-dihydroxyeicosa-5,8,11-trienoate
14,15-dihydroxy-5z,8z,11z-eicosatrienoate
14,15-dihydroxyeicosa-5,8,11-trienoic acid
Q27132938
14,15-dhet-[d11]
(+/-)14,15-dhet
192461-94-2

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 1,3-dicyclohexylurea (DCU), a potent sEH inhibitor, lowers systemic blood pressure in spontaneously hypertensive rats when dosed intraperitoneally."( Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
Chiang, PC; Fujiwara, H; Ghosh, S; Roberds, SL; Selbo, JG; Wahlstrom, JL, 2008
)
0.35
" The enzyme assay was carried out in a 96-well plate format, and near perfect sigmoidal dose-response curves were obtained for 12 concentrations of each inhibitor in only 22 min, enabling precise determination of IC(50) values."( Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.
Hammock, BD; Huby, M; Hwang, SH; Morisseau, C; Schebb, NH, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
DHETAn icosanoid obtained by formal dihydroxylation across one of the double bonds of arachidonic acid.
secondary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to one other carbon and one hydrogen.
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (46)

PathwayProteinsCompounds
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cytochrome P450 monooxygenases pathway113
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via cytochrome P450 monooxygenases213
Arachidonate epoxygenase / epoxide hydrolase09
Arachidonic acid metabolism via CYP (Cytochromoe P450) pathway014

Bioassays (1)

Assay IDTitleYearJournalArticle
AID15429Level reaching in blood plasma of rat or human was determined2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (11.63)18.2507
2000's16 (37.21)29.6817
2010's21 (48.84)24.3611
2020's1 (2.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.90 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.08%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (97.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]